{
  "catalogId": "1f2e6156-e330-40a9-872b-328b94d93933",
  "name": "BERIGLOBIN P",
  "status": "",
  "category": "prescription",
  "registrationValidity": "valid",
  "registrationNumber": "125 38 29064 00",
  "treatmentDescriptions": "Substitution in - Primary antibody deficiency syndromes resulting from defective antibody synthesis. - Protracted transitory hypogammaglobulinaemia especially in premature infants .Prophylaxis of hepatitis A- Before exposure- Within 2 weeks after exposure בקשה לתוספת התוויה 28/4/2019Indications for subcutaneous administration (SCIg)Replacement therapy in adults, children and adolescents (0-18 years) in: •\t\tPrimary immunodeficiency syndromes with impaired antibody production (see section 4.4).•\t\tHypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic leukaemia (CLL), in whom prophylactic antibiotics have failed or are contra-indicated.•\t\tHypogammaglobulinaemia and recurrent bacterial infections in multiple myeloma (MM) patients •\t\tHypogammaglobulinaemia in patients pre- and post- allogeneic haematopoietic stem cell transplantation (HSCT)Indications for intramuscular administration (IMIg)Hepatitis A prophylaxisIn adults and children and adolescents (0-18 years)•\t\tPre-exposure prophylaxis, preferably in combination with vaccination, in unvaccinated individuals travelling in less than 2 weeks to areas of hepatitis A risk.•\t\tPost-exposure prophylaxis in unvaccinated individuals within 2 weeks of hepatitis A virus (HAV) exposure.Consideration should also be given to other official guidance on the appropriate use in hepatitis A prophylaxis. For long term hepatitis A prophylaxis, vaccination is recommended. הערה: הבקשה הינה בהתאם לנוהל EMA (25.2.15)- Guideline on core SmPC for human normal immunoglobulin for subcutaneous and intramuscular administration",
  "termsOfIssue": "Prescription required",
  "form": "solution for injection",
  "route": "i.m, s.c",
  "site": "",
  "method": "",
  "administrationNotes": "",
  "ingredients": "IMMUNOGLOBULINS, NORMAL HUMAN/ML",
  "codes": {
    "atc5": {
      "system": "WHO ATC Classification",
      "code": "J06BA01",
      "name": "IMMUNOGLOBULINS, NORMAL HUMAN, FOR EXTRAVASCULAR ADM."
    }
  },
  "contraindications": "",
  "sideEffect": "",
  "warnings": "תרופה מוגבלת לשימוש בבתי חולים או אשפוז יום ",
  "alternativeMedications": [],
  "packaging": [
    {
      "name": "BERIGLOBIN P 16 % 2 ML  1 PFS",
      "manufacturer": {
        "name": "סי אס אל",
        "countryOfOrigin": "IL"
      },
      "strength": {
        "value": 0,
        "unit": ""
      },
      "quantity": {
        "value": 1.0,
        "unit": "units"
      },
      "packagingDescription": "SYRINGE PREFILLED  GLASS TYPE I",
      "shelfLife": "30",
      "storageConditions": "",
      "codes": {
        "moh": "8684",
        "yarpa": "77199",
        "pharmasoft": "2071",
        "barcode": "7290000689210"
      },
      "manufacturersAdministrationRecommendation": "",
      "pricing": {
        "currency": "ILS",
        "maxWholesalePrice": 68.45550075,
        "retailMargin": 34.5,
        "maxRetailPrice": 92.07264851,
        "maxPriceWithVAT": 108.6457204
      }
    }
  ],
  "metadata": {
    "version": "1.4",
    "lastUpdated": "2025-07-31T00:31:34.506384"
  }
}